<SEC-DOCUMENT>0001193125-24-230874.txt : 20241002
<SEC-HEADER>0001193125-24-230874.hdr.sgml : 20241002
<ACCEPTANCE-DATETIME>20241002110655
ACCESSION NUMBER:		0001193125-24-230874
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20241002
FILED AS OF DATE:		20241002
DATE AS OF CHANGE:		20241002

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sanofi
		CENTRAL INDEX KEY:			0001121404
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				133529324
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31368
		FILM NUMBER:		241345787

	BUSINESS ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017
		BUSINESS PHONE:		33153774400

	MAIL ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI-AVENTIS
		DATE OF NAME CHANGE:	20040826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI SYNTHELABO SA
		DATE OF NAME CHANGE:	20010104
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d816263d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR <FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">For the month of
October 2024 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Commission File Number: <FONT STYLE="white-space:nowrap">001-31368</FONT> </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>SANOFI </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">(Translation of
registrant&#146;s name into English) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">46, avenue de la Grande Arm&eacute;e, 75017 Paris, FRANCE </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">(Address of principal executive offices) </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate
by check mark whether the registrant files or will file annual reports under cover Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">20-F</FONT> &#9746;&#8195;&#8195;Form <FONT STYLE="white-space:nowrap">40-F</FONT> &#9744; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">In September 2024, Sanofi published the press releases attached hereto as Exhibits 99.1 and 99.2 which are
incorporated herein by reference. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit Index </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:9pt; font-family:Times New Roman; ">Exhibit No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:9pt; font-family:Times New Roman; " ALIGN="center">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" NOWRAP>Exhibit&nbsp;99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d816263dex991.htm">Press Release dated September&nbsp;27, 2024: Dupixent approved in China as the first-ever biologic medicine for patients with COPD </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" NOWRAP>Exhibit 99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d816263dex992.htm">Press Release dated September&nbsp;27, 2024: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD </A></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">SIGNATURES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:9pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top">Dated: October&nbsp;2, 2024</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman">By&#8195;&#8195;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">SANOFI</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:9pt; font-family:Times New Roman">/s/ Alexandra Roger</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman">&#8195;&#8195;&#8195;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Name: Alexandra Roger</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman">Title: Head of Legal
Corporate&nbsp;&amp; Finance</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d816263dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-size:14pt"><B>Press Release</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g816263dsp001a.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>Dupixent approved in China as the first-ever biologic medicine for patients with COPD </I></FONT></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two
landmark phase 3 studies showing Dupixent significantly reduced exacerbations, improved lung function, and also improved health-related quality of life </P></TD>
<TD WIDTH="4%">&nbsp;</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">COPD is the most prevalent chronic respiratory disease in China, and is a priority within the government&#146;s Healthy
China 2030 public health plan </P></TD>
<TD WIDTH="4%">&nbsp;</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Dupixent is now approved in four indications across respiratory and dermatological diseases in China </P></TD>
<TD WIDTH="4%">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify"><B>Paris and Tarrytown, New York, Sept. 27, 2024. </B>The National Medical Products Administration (NMPA) in
China has approved Dupixent (dupilumab) as an <FONT STYLE="white-space:nowrap">add-on</FONT> maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils. Specifically, the
approval covers patients already on a combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA) and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and a LAMA if ICS is not appropriate. Dupixent for
the treatment of COPD has been approved in more than 30 countries worldwide, including the 27 countries in the EU. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><B><I>Professor Kang Jian </I></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; font-size:10pt; font-family:arial" ALIGN="justify">Chair of COPD Branch, Chinese Association of Chest Physicians, CMDA, Respiratory Department of First Hospital of China
Medical University </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>&#147;The impact of COPD extends far beyond the patient. Debilitating
breathlessness and irreversible lung damage make it difficult for patients to do simple daily tasks, placing a significant burden on family members, the central caregivers in Chinese families. The approval of Dupixent for COPD in China is critical,
as it fills a gap in targeted therapy for the disease and provides clinicians with a new treatment approach. This offers new hope for COPD patients who remain inadequately controlled even after triple therapy, as well as those who care for
them.&#148; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><B><I>Houman Ashrafian, MD, PhD </I></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; font-size:10pt; font-family:arial" ALIGN="justify">Executive Vice President, Head of Research and Development at Sanofi </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>&#147;China has the largest number of people living with COPD worldwide, and a significant proportion of
patients are uncontrolled on current therapies and desperate for an effective treatment option. The Dupixent COPD clinical program has furthered our scientific understanding of COPD, and given us a new way to think about which patients could benefit
most from such a treatment. With its well-established safety and efficacy profile, Dupixent is a long-awaited advancement for patients, caregivers, and physicians who are desperate for a new treatment option.&#148; </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">Despite the high prevalence and burden of COPD in China, public awareness is limited. The
<FONT STYLE="font-family:arial; font-size:10pt" COLOR="#0563c1"><U>Healthy China 2030</U></FONT><FONT STYLE="font-family:arial"> public health initiative includes a focus on addressing chronic respiratory diseases like COPD and aims to improve the
quality of life for patients with COPD.</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g816263dsp001b.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="right"><FONT STYLE="font-family:arial;background-color:#e6e6e6; font-size:10pt" COLOR="#2b579a">1</FONT><FONT
STYLE="font-family:arial">/</FONT><FONT STYLE="font-family:arial;background-color:#e6e6e6; font-size:10pt" COLOR="#2b579a">5</FONT><FONT STYLE="font-family:arial"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">The approval is based on results from the landmark BOREAS and NOTUS phase 3 studies, which evaluated
the efficacy and safety of Dupixent in adults with uncontrolled COPD with raised blood eosinophils. All patients were on background maximal <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> inhaled
therapy (nearly all on triple therapy). Dupixent significantly reduced COPD exacerbations by 30% and 34% compared to placebo in the BOREAS and NOTUS studies respectively. Dupixent significantly and rapidly improved lung function compared to placebo,
with improvements sustained at 52 weeks. Improvements in health-related quality of life (statistically significant in BOREAS and nominally significant in NOTUS) compared to placebo were also observed, as assessed by the St. George&#146;s Respiratory
Questionnaire (SGRQ). Data from both studies were published in separate manuscripts in <I>The New England Journal of Medicine </I>(<FONT STYLE="font-family:arial; font-size:10pt" COLOR="#0563c1"><U>BOREAS</U></FONT><FONT STYLE="font-family:arial">
and </FONT><FONT STYLE="font-family:arial; font-size:10pt" COLOR="#0563c1"><U>NOTUS</U></FONT><FONT STYLE="font-family:arial">). </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">Safety
results in both studies were generally consistent with the known safety profile of Dupixent in its approved indications. The most common side effects across indications include injection site reactions, conjunctivitis, conjunctivitis allergic,
arthralgia, oral herpes, and eosinophilia. Additional adverse reactions of injection site bruising, injection site induration, injection site rash, and injection site dermatitis were reported in the COPD studies. Adverse events more commonly
observed with Dupixent (<FONT STYLE="font-family:Times New Roman">&#8805;</FONT>5%) compared to placebo in either COPD study were back pain, <FONT STYLE="white-space:nowrap">COVID-19,</FONT> diarrhea, headache, and nasopharyngitis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><B><I>George D. Yancopoulos, M.D., Ph.D. </I></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial">Board <FONT STYLE="white-space:nowrap">co-Chair,</FONT> President, and Chief Scientific Officer at Regeneron </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>&#147;One in four people with COPD live in China, and many patients are unable to control their disease
with standard of care treatments and experience repeated hospitalizations from exacerbations and debilitating limitations on their quality of life. With millions of people in industrialized areas worldwide facing increased risk for developing COPD,
it is more important than ever to deliver innovative new options for this complex and notoriously <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT> disease. With this latest Dupixent approval,
patients in China have a novel treatment approach that has shown groundbreaking results by reducing exacerbations while also improving lung function and supporting a better quality of life.&#148; </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">Additional submissions for Dupixent in COPD are under review with regulatory authorities around the world, including in the US and Japan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>About COPD </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">COPD is a respiratory disease that damages the
lungs and causes progressive lung function decline. Symptoms include persistent cough, excessive mucus production, and shortness of breath that may impair the ability to perform routine daily activities, which may lead to sleep disturbances, anxiety
and depression. COPD is also associated with a significant health and economic burden due to recurrent acute exacerbations that require systemic corticosteroid treatment and/or lead to hospitalization. Smoking and exposure to noxious particles are
key risk factors for COPD, but even individuals who quit smoking can still have progressive lung disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">About half of COPD patients continue to
experience exacerbations despite being on triple inhaled therapy. Patients with an eosinophilic phenotype contribute to a ~30% increase in exacerbations and an increased risk of COPD-related
<FONT STYLE="white-space:nowrap">re-hospitalizations</FONT> within a year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g816263dsp001b.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="right"><FONT STYLE="font-family:arial;background-color:#e6e6e6; font-size:10pt" COLOR="#2b579a">2</FONT><FONT
STYLE="font-family:arial">/</FONT><FONT STYLE="font-family:arial;background-color:#e6e6e6; font-size:10pt" COLOR="#2b579a">5</FONT><FONT STYLE="font-family:arial"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>About Sanofi and Regeneron&#146;s COPD Clinical Research Program </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">Sanofi and Regeneron are motivated to transform the treatment paradigm of COPD by examining the role different types of inflammation play in the disease
progression through the investigation of two potentially <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> biologics, Dupixent and itepekimab. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">Dupixent inhibits the signaling of the <FONT STYLE="white-space:nowrap">interleukin-4</FONT> (IL4) and
<FONT STYLE="white-space:nowrap">interleukin-13</FONT> (IL13) pathways and the program focuses on a specific population of people with evidence of <FONT STYLE="white-space:nowrap">type-2</FONT> inflammation. Itepekimab is a fully human monoclonal
antibody that binds to and inhibits <FONT STYLE="white-space:nowrap">interleukin-33</FONT> (IL33), an initiator and amplifier of broad inflammation in COPD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">Itepekimab is currently under clinical investigation for COPD in two phase 3 studies and its safety and efficacy have not been evaluated by any
regulatory authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>About Dupixent </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">Dupixent is
available in China in a 300 mg dose as a <FONT STYLE="white-space:nowrap">pre-filled</FONT> syringe or <FONT STYLE="white-space:nowrap">pre-filled</FONT> pen and is now available for COPD. Dupixent is intended for injection under the skin
(subcutaneous injection) and is given every other week. It can be given in a clinic or at home by self-administration after training by a healthcare professional. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">Dupixent (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the <FONT STYLE="white-space:nowrap">interleukin-4</FONT> (IL4)
and <FONT STYLE="white-space:nowrap">interleukin-13</FONT> (IL13) pathways and is not an immunosuppressant. The Dupixent development program has shown significant clinical benefit and a decrease in <FONT STYLE="white-space:nowrap">type-2</FONT>
inflammation in phase 3 studies, establishing that IL4 and IL13 are key and central drivers of the <FONT STYLE="white-space:nowrap">type-2</FONT> inflammation that plays a major role in multiple related and often
<FONT STYLE="white-space:nowrap">co-morbid</FONT> diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">Dupixent has received regulatory approvals in more than 60 countries in one or more
indications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, chronic spontaneous urticaria, and COPD in different age populations. More than 1,000,000
patients are being treated with Dupixent globally. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Dupilumab development program </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. To date, dupilumab has been studied across more than
60 clinical studies involving more than 10,000 patients with various chronic diseases driven in part by <FONT STYLE="white-space:nowrap">type-2</FONT> inflammation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">In addition to the currently approved indications, Sanofi and Regeneron are studying dupilumab in a broad range of diseases driven by <FONT
STYLE="white-space:nowrap">type-2</FONT> inflammation or other allergic processes in phase 3 studies, including chronic pruritus of unknown origin and bullous pemphigoid. These potential uses of dupilumab are currently under clinical investigation,
and the safety and efficacy in these conditions have not been fully evaluated by any regulatory authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>About Regeneron </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious
diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g816263dsp001b.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="right"><FONT STYLE="font-family:arial;background-color:#e6e6e6; font-size:10pt" COLOR="#2b579a">3</FONT><FONT
STYLE="font-family:arial">/</FONT><FONT STYLE="font-family:arial;background-color:#e6e6e6; font-size:10pt" COLOR="#2b579a">5</FONT><FONT STYLE="font-family:arial"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">
most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and
metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">Regeneron pushes the boundaries of
scientific discovery and accelerates drug development using our proprietary technologies, such as <I>VelociSuite</I><I><SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP></I><I>,</I> which produces optimized fully human antibodies and new
classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP><I> </I>and pioneering genetic medicine platforms,
enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">For more information, please visit <FONT
STYLE="font-family:arial; font-size:10pt" COLOR="#0563c1"><U>www.Regeneron.com</U></FONT><FONT STYLE="font-family:arial"> or follow Regeneron on </FONT><FONT STYLE="font-family:arial; font-size:10pt" COLOR="#0563c1"><U>LinkedIn</U></FONT><FONT
STYLE="font-family:arial"><U>,
</U></FONT><FONT STYLE="font-family:arial; font-size:10pt" COLOR="#0563c1"><U>Instagram</U></FONT><FONT STYLE="font-family:arial">,&nbsp;</FONT><FONT STYLE="font-family:arial; font-size:10pt" COLOR="#0563c1"><U>Facebook</U></FONT><FONT
STYLE="font-family:arial"><U></U>&nbsp;or&nbsp;</FONT><FONT STYLE="font-family:arial; font-size:10pt" COLOR="#0563c1"><U>X</U></FONT><FONT STYLE="font-family:arial">. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>About Sanofi </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">We are
an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people&#146;s lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into
the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial">Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>Sanofi Media Relations </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Sandrine
Guendoul </B>| + 33 6 25 09 14 25 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>sandrine.guendoul@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Evan Berland</B><B></B>&nbsp;|&nbsp;+ 1 215 432 0234 |<U></U>&nbsp;<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>evan.berland@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Victor Rouault</B> | + 33 6 70 93 71 40 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>victor.rouault@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Timothy
Gilbert</B><B></B>&nbsp;|&nbsp;+ 1 516 521 2929 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>timothy.gilbert@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>Sanofi Investor Relations </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Thomas
Kudsk Larsen</B> |+ 44 7545 513 693 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>thomas.larsen@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Aliz&eacute; Kaisserian</B><B></B>&nbsp;|&nbsp;+ 33 6 47 04 12 11 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>alize.kaisserian@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Arnaud
Del&eacute;pine</B><B></B>&nbsp;|&nbsp;+ 33 6 73 69 36 93 |<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>arnaud.delepine@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Felix Lauscher</B><B></B>&nbsp;|&nbsp;+ 1&nbsp;908&nbsp;612 7239 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>felix.lauscher@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Keita
Browne</B><B></B>&nbsp;|&nbsp;+ 1 781 249 1766 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>keita.browne@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Nathalie Pham</B><B></B>&nbsp;|&nbsp;+ 33 7 85 93 30 17 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>nathalie.pham@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Tarik Elgoutni </B>| + 1 617 710 3587 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>tarik.elgoutni@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Thibaud
Ch&acirc;telet</B> | + 33 6 80 80 89 90 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>thibaud.chatelet@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>Regeneron Media Relations </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Hannah
Kwagh </B>| +1 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">914-847-6314|</FONT></FONT> <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>hannah.kwagh@regeneron.com </U></FONT><FONT STYLE="font-family:arial">
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>Regeneron Investor Relations </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Vesna Tosic </B>| + <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">914-847-5443</FONT></FONT> | <FONT
STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>vesna.tosic@regeneron.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #b7b7b7">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Sanofi forward-looking statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="justify">This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking
statements are generally identified by the words &#147;expects&#148;, &#147;anticipates&#148;, &#147;believes&#148;, &#147;intends&#148;, &#147;estimates&#148;, &#147;plans&#148; and similar expressions. Although Sanofi&#146;s management believes
that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual results and developments to differ materially </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g816263dsp001b.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="right"><FONT STYLE="font-family:arial;background-color:#e6e6e6; font-size:10pt" COLOR="#2b579a">4</FONT><FONT
STYLE="font-family:arial">/</FONT><FONT STYLE="font-family:arial;background-color:#e6e6e6; font-size:10pt" COLOR="#2b579a">5</FONT><FONT STYLE="font-family:arial"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:arial" ALIGN="justify">
from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or
delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future
clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future
litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the
financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by
Sanofi, including those listed under &#147;Risk Factors&#148; and &#147;Cautionary Statement Regarding Forward-Looking Statements&#148; in Sanofi&#146;s annual report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> for the year ended
December&nbsp;31, 2023. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:7pt; font-family:arial" ALIGN="justify">All trademarks mentioned in this press release are the property of the Sanofi group with the exception of VelociSuite and Regeneron Genetics Center. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:7pt; font-family:arial"><B>Regeneron Forward-Looking Statements and Use of Digital Media </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:arial" ALIGN="justify">This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of
Regeneron Pharmaceuticals, Inc. (&#147;Regeneron&#148; or the &#147;Company&#148;), and actual events or results may differ materially from these forward-looking statements. Words such as &#147;anticipate,&#148; &#147;expect,&#148;
&#147;intend,&#148; &#147;plan,&#148; &#147;believe,&#148; &#147;seek,&#148; &#147;estimate,&#148; variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking
statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by
Regeneron and/or its collaborators or licensees (collectively, &#147;Regeneron&#146;s Products&#148;) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, &#147;Regeneron&#146;s Product
Candidates&#148;) and research and clinical programs now underway or planned, including without limitation Dupixent<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (dupilumab) as an <FONT STYLE="white-space:nowrap">add-on</FONT>
maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease characterized by raised blood eosinophils (&#147;COPD&#148;); uncertainty of the utilization, market acceptance, and commercial success of Regeneron&#146;s
Products and Regeneron&#146;s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing or
any potential regulatory approval of Regeneron&#146;s Products (such as Dupixent) and Regeneron&#146;s Product Candidates (such as itepekimab); the likelihood, timing, and scope of possible regulatory approval and commercial launch of
Regeneron&#146;s Product Candidates and new indications for Regeneron&#146;s Products, such as Dupixent for the treatment of COPD in the United States, Japan, and other jurisdictions as well as Dupixent for the treatment of chronic pruritus of
unknown origin, bullous pemphigoid, and other potential indications; the ability of Regeneron&#146;s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling,
distribution, and other steps related to Regeneron&#146;s Products and Regeneron&#146;s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates; safety issues resulting from the
administration of Regeneron&#146;s Products (such as Dupixent) and Regeneron&#146;s Product Candidates (such as itepekimab) in patients, including serious complications or side effects in connection with the use of Regeneron&#146;s Products and
Regeneron&#146;s Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron&#146;s ability to continue to develop or commercialize Regeneron&#146;s Products
and Regeneron&#146;s Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron&#146;s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of
reimbursement of Regeneron&#146;s Products from third-party payers, including private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and
Medicaid; coverage and reimbursement determinations by such payers and new policies and procedures adopted by such payers; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron&#146;s Products and
Regeneron&#146;s Product Candidates; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product
candidates to clinical trials, therapeutic applications, or regulatory approval; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and
changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron&#146;s agreements with Sanofi and Bayer (or their respective affiliated companies, as
applicable) to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics (such as the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic) on Regeneron&#146;s business; and risks associated with intellectual
property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (aflibercept)
Injection), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S.
Attorney&#146;s Office for the District of Massachusetts), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron&#146;s business, prospects, operating results, and financial
condition. A more complete description of these and other material risks can be found in Regeneron&#146;s filings with the U.S. Securities and Exchange Commission, including its Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended
December&nbsp;31, 2023 and its Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly period ended June&nbsp;30, 2024. Any forward-looking statements are made based on management&#146;s current beliefs and judgment, and the reader is
cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or
guidance, whether as a result of new information, future events, or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:7pt; font-family:arial" ALIGN="justify">Regeneron uses its media and investor relations website and social
media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron&#146;s media and
investor relations website (https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g816263dsp001b.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="right"><FONT STYLE="font-family:arial;background-color:#e6e6e6; font-size:10pt" COLOR="#2b579a">5</FONT><FONT
STYLE="font-family:arial">/</FONT><FONT STYLE="font-family:arial;background-color:#e6e6e6; font-size:10pt" COLOR="#2b579a">5</FONT><FONT STYLE="font-family:arial"> </FONT></P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d816263dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:14pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:14pt; font-family:arial"><B>Press Release</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g816263dsp001a.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
</I></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an
eosinophilic phenotype </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Following recent approvals in the EU and China, the US approval is based on two landmark phase 3 studies that showed
Dupixent achieved significant reduction in exacerbations, and also showed improvements in lung function and health-related quality of life compared to placebo </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Dupixent is the leading biologic medicine for all of its <FONT STYLE="white-space:nowrap">FDA-approved</FONT> indications
in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">new-to-brand</FONT></FONT> prescriptions, and the most prescribed biologic by pulmonologists in the US </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Paris and Tarrytown, NY, September</B><B></B><B>&nbsp;27, 2024. </B>The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an <FONT
STYLE="white-space:nowrap">add-on</FONT> maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. Dupixent is the first biologic medicine approved in the US to treat
these patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><B><I>Jean Wright, M.D. </I></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial">Chief Executive Officer at The COPD Foundation </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>&#147;People living with inadequately controlled COPD have long awaited new medicines to help manage the
daily suffering they experience from breathlessness, coughing, wheezing, exhaustion and unpredictable hospitalization. These patients often struggle with everyday activities many people take for granted such as taking a walk or running errands
outside the home. We welcome the approval of this new therapeutic option to offer patients a new way to help gain better control of their disease.&#148; </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><B><I>Paul Hudson </I></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial">Chief Executive Officer at Sanofi </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>&#147;Dupixent has already shown it can revolutionize the treatment paradigm of many diseases driven in
part by type 2 inflammation with high unmet medical needs, with one million patients being treated globally across all currently approved indications. With today&#146;s approval, Dupixent once again paves the way and becomes the first and only
approved <FONT STYLE="white-space:nowrap">add-on</FONT> biologic medicine for inadequately controlled COPD, giving patients living with this devastating disease the chance to look forward to the potential of improved breathing and a life with fewer
exacerbations.&#148; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The FDA approval is based on data from two landmark pivotal phase 3 studies
(<FONT STYLE="font-family:arial; font-size:10pt" COLOR="#0563c1"><U>BOREAS</U></FONT><FONT STYLE="font-family:arial"> and </FONT><FONT STYLE="font-family:arial; font-size:10pt" COLOR="#0563c1"><U>NOTUS</U></FONT><FONT STYLE="font-family:arial">)
that evaluated the efficacy and safety of Dupixent compared to placebo in adults currently on maximal <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> inhaled therapy (nearly all on triple therapy)
with inadequately controlled COPD and blood eosinophils <FONT STYLE="font-family:Times New Roman">&#8805;</FONT>300 cells per &micro;L. Patients who received Dupixent in BOREAS (n=468) and NOTUS (n=470) experienced the following outcomes,
respectively, compared to placebo (BOREAS n=471; NOTUS n=465): </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g816263dsp001b.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="background-color:#e6e6e6; " COLOR="#2b579a">1</FONT><FONT COLOR="#2b579a">/</FONT><FONT STYLE="background-color:#e6e6e6; " COLOR="#2b579a">6</FONT></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">30% and 34% reduction in the annualized rate of moderate or severe COPD exacerbations over 52 weeks, the primary
endpoint. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">74mL and 68mL numerically greater improvements in post-bronchodilator FEV<SUB
STYLE="font-size:75%; vertical-align:bottom">1</SUB> from baseline at week 12 compared to placebo, sustained at 52 weeks. Statistically significant improvements of similar magnitude were observed in
<FONT STYLE="white-space:nowrap">pre-bronchodilator</FONT> FEV<SUB STYLE="font-size:75%; vertical-align:bottom">1</SUB> from baseline at 12 and 52 weeks, a key secondary endpoint. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">51% response in a health-related quality of life measure in both trials compared to 43% and 47% with placebo at 52
weeks, as assessed by a <FONT STYLE="white-space:nowrap">4-point</FONT> improvement on the St. George&#146;s Respiratory Questionnaire (SGRQ). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Safety results in both studies were generally consistent with the known safety profile of Dupixent in its approved indications. In pooled BOREAS and NOTUS data, the
most common adverse events (<U>&gt;</U>2%) more frequently observed in patients on Dupixent compared to placebo were viral infection, headache, nasopharyngitis, back pain, diarrhea, arthralgia, urinary tract infection, local administration reaction,
rhinitis, eosinophilia, toothache, and gastritis. While less common, cholecystitis was reported in 0.6% of patients on Dupixent compared to 0.1% of patients on placebo. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><B><I>George D. Yancopoulos, M.D., Ph.D. </I></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial">Board <FONT STYLE="white-space:nowrap">Co-Chair,</FONT> President and Chief Scientific Officer at Regeneron </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>&#147;This latest FDA approval for Dupixent represents new hope for the hundreds of thousands of COPD
patients in the US who can sometimes struggle just to breathe during their everyday lives. Dupixent has a proven track record as a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> medicine, providing
benefit to the many patients suffering from type 2 inflammatory related diseases such as asthma and atopic dermatitis. This latest approval represents an important next chapter for Dupixent, giving those with COPD a novel option that has
demonstrated the unprecedented ability to help patients experience fewer exacerbations, while also helping them breathe better and improve quality of life in phase 3 studies.&#148; </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The FDA evaluated Dupixent under Priority Review, which is reserved for medicines that represent potentially significant improvements in efficacy or safety in treating
serious conditions. In July 2024, Sanofi and Regeneron announced that the European Medicines Agency approved Dupixent as an <FONT STYLE="white-space:nowrap">add-on</FONT> maintenance treatment for adults with uncontrolled COPD characterized by
raised blood eosinophils.&nbsp;Submissions are currently under review with other regulatory authorities around the world, including in Japan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>About COPD
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">COPD is a respiratory disease that damages the lungs and causes progressive lung function decline and is the fourth leading cause of death worldwide. Symptoms
include persistent cough, excessive mucus production and shortness of breath that may impair the ability to perform routine daily activities, which may lead to sleep disturbances, anxiety, and depression. COPD is also associated with a significant
health and economic burden due to recurrent acute exacerbations that require systemic corticosteroid medicine and/or antibiotics. Smoking and exposure to noxious particles are key risk factors for COPD, but even individuals who quit smoking can
still have progressive lung disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">About half of COPD patients continue to experience exacerbations despite being on triple inhaled therapy. In the US,
approximately 300,000 people live with inadequately controlled COPD and an eosinophilic phenotype. Patients with an eosinophilic phenotype contribute to an ~30% increase in exacerbations and an increased risk of COPD-related <FONT
STYLE="white-space:nowrap">re-hospitalizations</FONT> within a year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g816263dsp001b.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="background-color:#e6e6e6; " COLOR="#2b579a">2</FONT><FONT COLOR="#2b579a">/</FONT><FONT STYLE="background-color:#e6e6e6; " COLOR="#2b579a">6</FONT></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>About the Dupixent COPD phase 3 study program </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">BOREAS and NOTUS were replicate, randomized, phase 3, double-blind, placebo-controlled studies that evaluated the efficacy and safety of Dupixent in adults who were
current or former smokers with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> COPD with an eosinophilic phenotype, as defined by blood eosinophils
<FONT STYLE="font-family:Times New Roman">&#8805;</FONT>300 cells per &micro;L. The studies included adults with COPD across a broad range of clinical presentations, including those with chronic bronchitis and emphysema. The studies enrolled 1,874
patients who were aged 40 to 80 years in BOREAS and 40 to 85 years in NOTUS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the <FONT STYLE="white-space:nowrap">52-week</FONT> treatment period, patients
in BOREAS and NOTUS received Dupixent or placebo every two weeks added to a maximal <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> inhaled triple therapy of ICS, LABA and LAMA. Double maintenance
therapy, which included LABA and LAMA, was allowed if ICS was not appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The primary endpoint for BOREAS and NOTUS evaluated the annualized rate of acute
moderate or severe COPD exacerbations. Key secondary endpoints included change from baseline in lung function (assessed by <FONT STYLE="white-space:nowrap">pre-bronchodilator</FONT> forced expiratory volume [FEV<SUB
STYLE="font-size:75%; vertical-align:bottom">1</SUB>]) at 12 and 52 weeks, change from baseline at 52 weeks in SGRQ total score compared to placebo, and safety. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The results of both <FONT STYLE="font-family:arial; font-size:10pt" COLOR="#0563c1"><U>BOREAS</U></FONT><FONT STYLE="font-family:arial"> and </FONT><FONT
STYLE="font-family:arial; font-size:10pt" COLOR="#0563c1"><U>NOTUS</U></FONT><FONT STYLE="font-family:arial"> were separately published in <I>The New England Journal of Medicine</I>. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>About Sanofi and Regeneron&#146;s COPD Clinical Research Program </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Sanofi and
Regeneron are motivated to transform the treatment paradigm of COPD by examining the role different types of inflammation play in the disease progression through Dupixent, a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> biologic, and the investigation of itepekimab. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Dupixent inhibits the
signaling of the <FONT STYLE="white-space:nowrap">interleukin-4</FONT> (IL4) and <FONT STYLE="white-space:nowrap">interleukin-13</FONT> (IL13) pathways and the program focuses on a specific population of people with evidence of type 2 inflammation.
Itepekimab is a fully human monoclonal antibody that binds to and inhibits <FONT STYLE="white-space:nowrap">interleukin-33</FONT> (IL33), an initiator and amplifier of broad inflammation in COPD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Itepekimab is currently under clinical investigation for COPD in two phase 3 studies and its safety and efficacy have not been evaluated by any regulatory authority.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>About Dupixent </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Dupixent is a fully human monoclonal antibody that
inhibits the signaling of the IL4 and IL13 pathways and is not an immunosuppressant. The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in phase 3 studies, establishing that IL4 and IL13 are
two of the key and central drivers of type 2 inflammation that play a major role in multiple related and often <FONT STYLE="white-space:nowrap">co-morbid</FONT> diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Sanofi and Regeneron are committed to helping patients in the US who are prescribed Dupixent gain access to the medicine and receive the support they may need with the
DUPIXENT <I>MyWay</I><I><SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP></I> program. For more information, please call <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-844-DUPIXENT</FONT></FONT> <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(1-844-387-4936)</FONT></FONT></FONT> or visit <FONT STYLE="font-family:arial; font-size:10pt" COLOR="#0563c1"><U>www.DUPIXENT.com</U></FONT><FONT
STYLE="font-family:arial">. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with
atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, chronic spontaneous urticaria, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g816263dsp001b.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="background-color:#e6e6e6; " COLOR="#2b579a">3</FONT><FONT COLOR="#2b579a">/</FONT><FONT STYLE="background-color:#e6e6e6; " COLOR="#2b579a">6</FONT></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
and COPD in different age populations. More than 1,000,000 patients are being treated with Dupixent globally. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Dupilumab Development Program </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Dupilumab is being jointly developed by Sanofi
and Regeneron under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical studies involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to the currently approved indications, Sanofi and Regeneron are studying dupilumab in a broad range of diseases driven in part by type 2 inflammation or
other allergic processes in phase 3 studies, including chronic pruritus of unknown origin and bullous pemphigoid. These potential uses of dupilumab are currently under clinical investigation, and the safety and efficacy in these conditions have not
been fully evaluated by any regulatory authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>About Regeneron </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents,&nbsp;develops&nbsp;and commercializes life-transforming medicines for people with serious
diseases. Founded and led by physician-scientists, our unique ability to&nbsp;repeatedly and consistently translate science&nbsp;into medicine has led to numerous approved treatments and&nbsp;product candidates in development, most of which were
homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions,
infectious&nbsp;diseases, and rare diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Regeneron&nbsp;pushes the boundaries of scientific discovery and&nbsp;accelerates drug development&nbsp;using&nbsp;our
proprietary technologies, such as<I>&nbsp;VelociSuite</I><I><SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP></I>, which produces optimized fully human antibodies and new classes of bispecific antibodies.&nbsp;We are shaping the next
frontier of medicine with data-powered insights from the&nbsp;Regeneron Genetics Center<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>&nbsp;and pioneering genetic medicine platforms, enabling us to identify innovative targets and
complementary approaches to potentially treat or cure diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For more information, please visit
<FONT STYLE="font-family:arial; font-size:10pt" COLOR="#0563c1"><U>www.Regeneron.com</U></FONT><FONT STYLE="font-family:arial"> or follow Regeneron on </FONT><FONT STYLE="font-family:arial; font-size:10pt" COLOR="#0563c1"><U>LinkedIn</U></FONT><FONT
STYLE="font-family:arial">, </FONT><FONT STYLE="font-family:arial; font-size:10pt" COLOR="#0563c1"><U>Instagram</U></FONT><FONT STYLE="font-family:arial">, </FONT><FONT STYLE="font-family:arial; font-size:10pt" COLOR="#0563c1"><U>Facebook</U></FONT><FONT
STYLE="font-family:arial"> or </FONT><FONT STYLE="font-family:arial; font-size:10pt" COLOR="#0563c1"><U>X</U></FONT><FONT STYLE="font-family:arial">. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><FONT
 COLOR="#7a00e6"><I>About Sanofi </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve
people&#146;s lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to
millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial">Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>Media Relations </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Sandrine
Guendoul</B><B></B>&nbsp;|&nbsp;+ 33 6 25 09 14 25 |&nbsp;<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>sandrine.guendoul@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Evan Berland</B> | +1 215 432 0234 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>evan.berland@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Nicolas
Obrist</B><B></B>&nbsp;|&nbsp;+ 33 6 77 21 27 55 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>nicolas.obrist@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Victor Rouault</B><B></B>&nbsp;|&nbsp;+ 33 6 70 93 71 40 |<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>&nbsp;victor.rouault@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Timothy Gilbert</B><B></B>&nbsp;|&nbsp;+ 1 516 521 2929 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>timothy.gilbert@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#7a00e6"><I>Investor Relations </I></FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g816263dsp001b.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="background-color:#e6e6e6; " COLOR="#2b579a">4</FONT><FONT COLOR="#2b579a">/</FONT><FONT STYLE="background-color:#e6e6e6; " COLOR="#2b579a">6</FONT></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Thomas Kudsk Larsen</B> |+ 44 7545 513 693 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>thomas.larsen@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Aliz&eacute;
Kaisserian</B><B></B>&nbsp;|&nbsp;+ 33 6 47 04 12 11 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>alize.kaisserian@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Arnaud Del&eacute;pine</B><B></B>&nbsp;|&nbsp;+ 33 6 73 69 36 93 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>arnaud.delepine@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Felix
Lauscher</B><B></B>&nbsp;|&nbsp;+ 1&nbsp;908&nbsp;612 7239 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>felix.lauscher@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Keita Browne</B><B></B>&nbsp;|&nbsp;+ 1 781 249 1766 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>keita.browne@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Nathalie Pham</B><B></B>&nbsp;|&nbsp;+ 33 7 85 93 30 17 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>nathalie.pham@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Tarik Elgoutni </B>|
+ 1 617 710 3587 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>tarik.elgoutni@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Thibaud Ch&acirc;telet</B> | + 33 6 80 80 89 90 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>thibaud.chatelet@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>Regeneron Media Relations </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Hannah Kwagh </B>| +1 914 847 6314| <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>hannah.kwagh@regeneron.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>Regeneron Investor Relations </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Vesna Tosic </B>| + 914 847 5443 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>vesna.tosic@regeneron.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #b7b7b7">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:7pt; font-family:arial"><B>Sanofi Forward-Looking Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:arial" ALIGN="justify">This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking
statements are generally identified by the words &#147;expects&#148;, &#147;anticipates&#148;, &#147;believes&#148;, &#147;intends&#148;, &#147;estimates&#148;, &#147;plans&#148; and similar expressions. Although Sanofi&#146;s management believes
that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include
among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties
inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks
associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that pandemics or other global crises may have on us, our customers,
suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in
the public filings with the SEC and the AMF made by Sanofi, including those listed under &#147;Risk Factors&#148; and &#147;Cautionary Statement Regarding Forward-Looking Statements&#148; in Sanofi&#146;s annual report on Form <FONT
STYLE="white-space:nowrap">20-F</FONT> for the year ended December&nbsp;31, 2023. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:7pt; font-family:arial" ALIGN="justify">All trademarks mentioned in this press release are the property of the Sanofi group apart from VelociSuite and Regeneron Genetics Center.</P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:7pt; font-family:arial"><B>Regeneron Forward-Looking Statements and Use of Digital Media </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:arial" ALIGN="justify">This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of
Regeneron Pharmaceuticals, Inc. (&#147;Regeneron&#148; or the &#147;Company&#148;), and actual events or results may differ materially from these forward-looking statements. Words such as &#147;anticipate,&#148; &#147;expect,&#148;
&#147;intend,&#148; &#147;plan,&#148; &#147;believe,&#148; &#147;seek,&#148; &#147;estimate,&#148; variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking
statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by
Regeneron and/or its collaborators or licensees (collectively, &#147;Regeneron&#146;s Products&#148;) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, &#147;Regeneron&#146;s Product
Candidates&#148;) and research and clinical programs now underway or planned, including without limitation Dupixent<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (dupilumab) as an <FONT STYLE="white-space:nowrap">add-on</FONT>
maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (&#147;COPD&#148;) and an eosinophilic phenotype; uncertainty of the utilization, market acceptance, and commercial success of Regeneron&#146;s
Products and Regeneron&#146;s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing or
any potential regulatory approval of Regeneron&#146;s Products (such as Dupixent) and Regeneron&#146;s Product Candidates (such as itepekimab); the likelihood, timing, and scope of possible regulatory approval and commercial launch of
Regeneron&#146;s Product Candidates and new indications for Regeneron&#146;s Products, such as Dupixent for the treatment of COPD in Japan and other jurisdictions as well as Dupixent for the treatment of chronic pruritus of unknown origin, bullous
pemphigoid, and other potential indications; the ability of Regeneron&#146;s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps
related to Regeneron&#146;s Products and Regeneron&#146;s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates; safety issues resulting from the administration of Regeneron&#146;s Products
(such as Dupixent) and Regeneron&#146;s Product Candidates (such as itepekimab) in patients, including serious complications or side effects in connection with the use of Regeneron&#146;s Products and Regeneron&#146;s Product Candidates in clinical
trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron&#146;s ability to continue to develop or commercialize Regeneron&#146;s Products and Regeneron&#146;s Product Candidates; ongoing
regulatory obligations and oversight impacting Regeneron&#146;s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement of Regeneron&#146;s Products from
third-party payers, including private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations
by such payers and new policies and procedures adopted by such payers; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron&#146;s Products and Regeneron&#146;s Product Candidates; the extent to
which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g816263dsp001b.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="background-color:#e6e6e6; " COLOR="#2b579a">5</FONT><FONT COLOR="#2b579a">/</FONT><FONT STYLE="background-color:#e6e6e6; " COLOR="#2b579a">6</FONT></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:arial" ALIGN="justify">
replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; unanticipated expenses; the costs of developing,
producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply
agreement, including Regeneron&#146;s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable) to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics (such as the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic) on Regeneron&#146;s business; and risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation
and other related proceedings relating to EYLEA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (aflibercept) Injection), other litigation and other proceedings and government investigations relating to the Company and/or its operations
(including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney&#146;s Office for the District of Massachusetts), the ultimate outcome of any such proceedings and investigations, and the impact
any of the foregoing may have on Regeneron&#146;s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron&#146;s filings with the U.S. Securities and
Exchange Commission, including its Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2023 and its Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly period ended June&nbsp;30, 2024. Any
forward-looking statements are made based on management&#146;s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly
or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:7pt; font-family:arial" ALIGN="justify">Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including
information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron&#146;s media and investor relations website (<U>https://investor.regeneron.com</U>) and its
LinkedIn page (<U>https://www.linkedin.com/company/regeneron-pharmaceuticals</U>). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g816263dsp001b.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="background-color:#e6e6e6; " COLOR="#2b579a">6</FONT><FONT COLOR="#2b579a">/</FONT><FONT STYLE="background-color:#e6e6e6; " COLOR="#2b579a">6</FONT></TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g816263dsp001a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g816263dsp001a.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MM(O"/B/3_#]AI'AR[LK"&Y^U:8FHRW=Y<SV4\Q8;Q&J1-&."23Q@ [?]O_\
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MP5^+O08^&7COJ0 ,>%]4ZDT ?R>?\$V_^3T?@G_V&M5_]1[5: /UD_X+:_\
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M7)B)&'V17<*L1G!8 \T ?D[^U)_R>A\6_P#LM6H?^GV&@#^RWPW_ ,B]H/\
MV!=+_P#2&"@#^>?_ (+>?\E#^!__ &)?B'_T^+0!]\_\$B_^3,_#G_8]>/?_
M $[)0!\H?M,:;^U _P"T]K\VA6WQ'D)\20M\/;G1(]8?2(M%\V/^R19W%D#:
M0Q(N/M D9=K>89\*<G^]?#+$>%\?##+H8ZKDT8QP<EF\,5+#+$O$6E[?GA4:
MK3D_^7+@I7]WD/V[ARIPVN',/&M+"12I/ZU&HZ:J>TL^>ZE[[?\ )9/I8_<_
M1(K]] TB'7EBEU-M(L$UA"JO$]^;.(7P*D%60W'F\8Q^%?PKC_JWU[&?4KK!
M^WJ^P3W]C[27L[_]N<I^+5_9^VJ^QTI<\N3_  <SY?PL?R_?\%$OV4?';_M1
M^,K[X*_ [QM=^$-4TW0=7N+CPEX/U*Z\/3>(+ZP$VM2:<VFVC0)NNOFDBCV[
M96D^49YY#(_<KX(_ S_A)_V(?A]\"OC)I5U%+J?PJT_P[XGTR[&W4M)N)(FF
MML%\F+4=/E^RR(3]V2W"L" 00#^=_P".W_!/;]I_]G+QA<:EX2\.>)/&_AG3
M[Y[OPSX]^'D%Y>ZE#!'(6M9+_3-+SJ.D:I&FWS/+B>+(RDI#;0;>5@V\K'GN
MK^+OV]/B%I;>"M9O?VE_$^DW$7V&?0;JP\?W5K<0L-GV>\MS:;9HR.")LCUH
M ^X?^"=O["/[1WACX]^ OC'X\\%R> ?!_A">_P!0E7Q+<P6^MZHUQI5W906U
MCHT$DMQ"3)=@L]V+?:(SPQ(HV\@V\C[8_P""OOPR^(?Q+^%/PLL_AYX*\2>-
M+O2_'&IW.HVOAK2KK5[FRM[C1UAAGN+>SC>1(6E4IOVE0>I&:/T#]"+_ ((^
M_##XB?#'X6?%JS^(?@KQ+X*N]5\?:9=Z;:^)=)N](N;VUM_#\-O-<6]O>QQR
M20K,-F\+MSD G!HV\@V\CZ!_X*8^"O%WC_\ 9-\7>'?!'AO6/%6NOKOA>[BT
M;0K&;4=2EMK74"UQ+#9VZM+,L:L&81JQ YQQ0!\!_P#!'WX,?%GX:?$KXN:G
M\0?ASXP\%Z??^#-#LK&[\3:%?Z-#>7<>L3S/;VK7T,?VB58OG81AMHQG&1DV
M\@V\C[._X*%?L(Q_M6>'M,\6>![FPT?XO>#[.:TTR2_/V?3?%.CL[3_V#JEU
M'&S6MQ'.SO:W15PAD>-QY; H?H'Z'\_%IX$_;D_9@U?4=(T#0/CG\.KF:5H[
MQO!]MXCDT?4&C)195OO#RW%A> C!5Q(S8QTQ@&WD&WD=-\.?V.?VPOVK/&\>
MIZ_X<\;P?VE<1#7/B/\ %9-7T^"TM58+)/OUP+?:JZ1EC%!:1.&8!2\:MO !
M_4S^SE\!?"?[-OPF\-?"OPCNGMM'A:?5=7GC2.\U[7;LB74]8NP@PKS3YV1C
MY8XT1%X7DV^0;?(_F9_:1_9K_:!UG]KKXG:]I'P:^(VIZ'J/Q>NM0L-7L/"N
MK7>EWEA/K,,L-[;ZA!;M;R6K1$-YHDV*,EB-IP ?UB:##+;:'HUO,C130:5I
MT,L3<-'+%:0I(C ?Q*ZD'Z4 ?A9_P6$^#?Q7^)?C?X.:A\/?AWXO\:6.F^%=
M=LM0N?#.AWVLQV-W)JR3QP77V&*1H':'YUW@ CH<\4 ?;7_!+SP-XQ^'G[)G
MAWP[XZ\,ZUX2UY?%_C2^;1]?L)],U*.TO-4#VL\EG<JLL22HI*[U4D#.,$$F
MWD&WD?H:57(.!E?ND@9&>N#VIW:5KV78-O(6D 4 % !CMVZ8_P#K4 1K%$AR
MD<:GU5%4_F!0!)0 4 % !0 4 % #61'&'16 [,H8#\"* % "@  *!T & ,>@
-% "T % !0 4 % '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g816263dsp001b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g816263dsp001b.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
